<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. __)
Filed by the Registrant /X/
Filed by a Party other than the Registrant / /
Check the appropriate box:
/ / Preliminary Proxy Statement
/ / Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
/X/ Definitive Proxy Statement
/ / Definitive Additional Materials
/ / Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
PDK LABS INC.
------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
/x/ No fee required
/ / Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
/ / Fee paid previously with preliminary materials.
/ / Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
<PAGE>
PDK LABS INC.
145 RICEFIELD LANE
HAUPPAUGE, NEW YORK 11788
------------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON OCTOBER 29, 1999
------------------------
TO THE STOCKHOLDERS:
Notice is hereby given that the annual meeting of stockholders (the "Annual
Meeting") of PDK Labs Inc. (the "Company") has been called for and will be held
at 3:00 P.M., Eastern Standard Time, on October 29, 1999, at Sheraton Smithtown,
110 Vanderbilt Motor Parkway, Smithtown, N.Y. 11788 for the following purposes:
1. To elect a Board of Directors consisting of five (5) directors to
hold office until the next Annual Meeting and until their successors shall
have been elected and qualified;
2. To ratify the appointment by the Board of Directors of Holtz
Rubenstein & Co., LLP to serve as the independent certified public
accountants for the current fiscal year; and
3. To consider and transact such other business as may properly come
before the Annual Meeting or any adjournments thereof.
The Board of Directors has fixed the close of business on September 2, 1999
as the record date for the determination of the stockholders entitled to notice
of, and to vote at, the Annual Meeting or any adjournments thereof. The list of
stockholders entitled to vote at the Annual Meeting will be available for the
examination of any stockholder at the Company's offices at 145 Ricefield Lane,
Hauppauge, New York 11788, for ten days prior to October 29, 1999.
By Order of the Board of Directors
Reginald Spinello
President
Dated: September 8, 1999
WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE FILL IN, SIGN, AND
DATE THE PROXY SUBMITTED HEREWITH AND RETURN IT IN THE ENCLOSED STAMPED
ENVELOPE. THE GIVING OF SUCH PROXY WILL NOT AFFECT YOUR RIGHT TO REVOKE SUCH
PROXY IN PERSON SHOULD YOU LATER DECIDE TO ATTEND THE MEETING. THE ENCLOSED
PROXY IS BEING SOLICITED BY THE BOARD OF DIRECTORS.
<PAGE>
PDK LABS INC.
PROXY STATEMENT
GENERAL
This proxy statement is furnished by the Board of Directors of PDK Labs
Inc., a New York corporation (the "Company"), with offices located at 145
Ricefield Lane, Hauppauge, New York 11788, in connection with the solicitation
of proxies to be used at the annual meeting of stockholders of the Company (the
"Annual Meeting") to be held on October 29, 1999, and at any adjournments
thereof. This proxy statement will be mailed to stockholders beginning
approximately September 8, 1999. If a proxy in the accompanying form is properly
executed and returned, the shares represented thereby will be voted as
instructed on the proxy. Any proxy may be revoked by a stockholder prior to its
exercise upon written notice to the President of the Company, or by a
stockholder voting in person at the Annual Meeting.
All properly executed proxies received prior to the Annual Meeting will be
voted at the Annual Meeting in accordance with the instructions marked thereon
or otherwise as provided therein.
At the Annual Meeting, Stockholders will be asked to approve and consent:
1. To elect a Board of Directors consisting of five (5) directors to
hold office until the next Annual Meeting and until their successors shall
have been elected and qualified;
2. To ratify the appointment by the Board of Directors of Holtz
Rubenstein & Co., LLP, to serve as the independent certified public
accountants for the current fiscal year; and
3. To consider and transact such other business as may properly come
before the Annual Meeting or any adjournments thereof.
Under the Certificate of Incorporation of the Company and under the New
York Business Corporation Law (i) the nominees to be selected as a Director in
Proposal 1 must receive a plurality of the votes represented by shares of Common
Stock present or represented at the Annual Meeting and entitled to vote on the
election of directors, and (ii) the affirmative vote of a majority of the votes
represented by shares of Common Stock present or represented at the Annual
Meeting is necessary to ratify the appointment of Holtz Rubenstein & Co., LLP.
Unless instructions to the contrary are indicated, proxies will be voted "FOR"
the election of five (5) directors and "FOR" the ratification of the selection
by the Board of Directors of Holtz Rubenstein & Co., LLP as the independent
certified public accountants of the Company.
A COPY OF THE COMPANY'S ANNUAL REPORT ON FORM 10-K FOR FISCAL YEAR ENDED
NOVEMBER 30, 1998 (THE "FORM 10-K"), WHICH CONTAINS FINANCIAL STATEMENTS AUDITED
BY THE COMPANY'S INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS, ACCOMPANIES THIS
PROXY STATEMENT AND IS INCORPORATED HEREIN BY REFERENCE.
The Board of Directors does not know of any matter to be proposed for
action at the Annual Meeting other than those described in this proxy statement.
If other matters properly come before the Annual Meeting, the persons named in
the accompanying proxy will act in accordance with their best judgment.
The cost of preparing, assembling and mailing this notice of Annual
Meeting, proxy statement, the enclosed Form 10-K and proxy will be borne by the
Company. In addition to solicitation of the proxies by use of the mails, some of
the officers and regular employees of the Company, for no additional
remuneration, may solicit proxies personally or by telephone, telegraph, or
cable. The Company may also request brokerage houses, nominees, custodians and
fiduciaries to forward soliciting material to the beneficial owners of Common
Stock held of record. The Company will reimburse such persons for their expenses
in forwarding soliciting material.
<PAGE>
VOTING SECURITIES AND
PRINCIPAL HOLDERS THEREOF
The Board of Directors has fixed the close of business on September 2, 1999
as the record date (the "Record Date") for the determination of stockholders
entitled to notice of, and to vote at, the Annual Meeting and any adjournments
thereof. Only stockholders on the Record Date will be able to vote at the Annual
Meeting, and each holder of record of Common Stock will be entitled to one vote
for each share held, with no shares having cumulative voting rights.
As of the Record Date, there were 3,807,153 shares of Common Stock issued
and outstanding, all of which are entitled to one (1) vote per share at the
Annual Meeting. Holders of the Common Stock are entitled to vote on all matters.
Unless otherwise indicated herein, a majority of the votes represented by the
shares of Common Stock present or represented at the Annual Meeting is required
for approval of each matter which will be submitted to stockholders.
Management of the Company knows of no business other than those matters
specified in Items 1 and 2 of the Notice of Annual Meeting which will be
presented for consideration at the Annual Meeting. If any other matter is
properly presented, it is the intention of the persons named in the enclosed
proxy to vote in accordance with their best judgment.
The following table sets forth certain information, as of September 2, 1999
with respect to the beneficial ownership of the outstanding Common Stock by
(i) any holder of more than five percent (5%); (ii) each of the Company's
officers and directors; and (iii) the directors and officers of the Company as a
group:
<TABLE>
<CAPTION>
AMOUNT AND NATURE OF APPROXIMATE
BENEFICIAL PERCENT
NAME AND ADDRESS OF BENEFICIAL OWNER OWNERSHIP(1) OF CLASS
- ----------------------------------------------------------------- -------------------- -----------
<S> <C> <C>
Perry D. Krape................................................... 205,488 8.2%
c/o PDK Labs Inc.
145 Ricefield Lane
Hauppauge, NY 11788
Reginald Spinello(2)............................................. 672,500 26.9%
PDK Labs Inc.
145 Ricefield Lane
Hauppauge, NY 11788
Michael Krasnoff(3).............................................. 200,000 8.0%
PDK Labs Inc.
145 Ricefield Lane
Hauppauge, NY 11788
Thomas Keith..................................................... 0 0
c/o Compare Generiks, Inc.
60 Davids Drive
Hauppauge, NY 11788
Lawrence Simon................................................... 0 0
c/o Superior Supplements, Inc.
270 Oser Avenue
Hauppauge, NY 11788
Karine Hollander(4).............................................. 50,000 2.0%
c/o PDK Labs Inc.
145 Ricefield Lane
Hauppauge, NY 11788
</TABLE>
2
<PAGE>
<TABLE>
<CAPTION>
AMOUNT AND NATURE OF APPROXIMATE
BENEFICIAL PERCENT
NAME AND ADDRESS OF BENEFICIAL OWNER OWNERSHIP(1) OF CLASS
- ----------------------------------------------------------------- ------------- ------------
<S> <C> <C>
Ira Helman....................................................... 0 0
c/o PDK Labs Inc.
145 Ricefield Lane
Hauppauge, NY 11788
Dune Holdings, Inc.(3)........................................... 200,000 8.0%
132 Dune Road
West Hampton, NY 11978
Directors and Officers 672,500 26.9%
as a Group (five (5) persons)....................................
</TABLE>
- ------------------
(1) Beneficial ownership as reported in the table above has been determined in
accordance with Instruction (4) to Item 403 of Regulation S-B of the
Securities Exchange Act.
(2) Includes 50,000 shares of common stock owned by Karine Hollander and 100,000
shares of Common Stock owned by Michael Lulkin, which are subject to a ten
(10) year voting trust held by the Company's Chief Executive Officer.
(3) Includes 200,000 shares of common stock owned by Dune Holdings, Inc., over
which Mr. Krasnoff possesses a voting trust and as to which Mr. Krasnoff
disclaims any beneficial ownership.
(4) Ms. Hollander's shares of Common Stock are subject to a ten (10) year voting
trust held by the Company's Chief Executive Officer.
PROPOSAL NO. 1:
ELECTION OF DIRECTORS
GENERAL
The Board of Directors consisted of five (5) persons as of the fiscal year
ended November 30, 1998 ("Fiscal 1998"). The directors are elected for a
one-year term or until their successors are elected and qualify with a plurality
of votes cast in favor of their election. Reginald Spinello, Ira Helman, Karine
Hollander, Thomas Keith and Lawrence Simon are the nominees for election to the
Board of Directors.
Unless otherwise directed by the stockholder giving the proxy, the proxies
in the accompanying form will be voted "FOR" the election of the nominees named
above as directors. If any nominee should subsequently become unavailable for
election, the persons voting the accompanying proxy may in their discretion vote
for a substitute.
BOARD OF DIRECTORS
The Board of Directors has the responsibility for managing the operations
of the Company but are not involved in day-to-day operating details. Members of
the Board are kept informed of the Company's business by various reports and
documents sent to them as well as by operating and financial presentations made
at Board meetings. The Board of Directors held eight (8) meetings (or executed
consents in lieu thereof) in Fiscal 1998, and all of the directors attended all
of the meetings of the Board. The Board of Directors has a standing Audit
Committee which has authority to retain the independent auditor for the Company
and to discuss the financial statements and related matters with said auditor
and which consists of Thomas A. Keith and Lawrence D. Simon.
All directors hold office until the next annual meeting of stockholders and
the election and qualification of their successors. Officers are elected
annually by the Board of Directors and, subject to existing employment
agreements, serve at the discretion of the Board.
Outside directors do not receive any compensation for their services.
Directors who are also officers of the Company do not receive any compensation
for serving on the Board of Directors. All directors are reimbursed by the
Company for any expenses incurred in attending Director's meetings.
3
<PAGE>
The following table sets forth certain information regarding the current
directors of the Company, the current executive officers of the Company and the
director nominees.
<TABLE>
<CAPTION>
NAME AGE POSITION
- ----------------------------------------------------- --- -----------------------------------------------------
<S> <C> <C>
Reginald Spinello.................................... 46 Chairman of the Board, Chief Executive Officer and
President
Karine Hollander..................................... 32 Chief Financial Officer, Secretary and Director
Thomas A. Keith...................................... 40 Director
Ira Helman........................................... 67 Director
Lawrence D. Simon.................................... 33 Director
</TABLE>
BACKGROUND OF EXECUTIVE OFFICERS AND DIRECTORS
Reginald Spinello has been the Chairman of the Board, Chief Executive
Officer and President since August 21, 1998 and a Director of the Company since
August 1997. Mr. Spinello was the Company's Executive Vice President since
September 1993. Mr. Spinello is also the President and a director of the
Company's subsidiary Futurebiotics, Inc. In addition, he has been a Director of
Superior Supplements, Inc. since May 1, 1996. Superior Supplements, Inc. ("SSI")
is a developer, manufacturer and marketer of dietary supplements in bulk tablet,
capsule and powder form. Prior to joining PDK Labs Inc., Mr. Spinello was
President and Founder of Internal Reinforcements from 1985 to 1991, a specialty
distributor and marketer of natural vitamins and supplements. Mr. Spinello
graduated from Bryant College with a B.S. Degree in Business Administration.
Additionally, he has studied in the field of nutrition and is a non-practicing
nutrition consultant.
Karine Hollander has been the Chief Financial Officer of the Company and
Futurebiotics, Inc. since March 3, 1997. In addition, she has been a Director of
the Company since March 11, 1998. She had been the Comptroller of PDK Labs Inc.
since September 1994. From 1989 until joining the Company, Ms. Hollander was
employed by the accounting firm of Holtz Rubenstein & Co., LLP. Ms. Hollander
received a B.A. degree in Accounting from Dowling College.
Thomas A. Keith has been a Director of the Company since March 11, 1998,
and he has been a Director of Futurebiotics, Inc. since December 2, 1998. In
addition, he has been a Director of Compare Generiks, Inc. since May 21, 1997
and the President of Compare Generiks, Inc. since October 31, 1995. Prior to
joining Compare Generiks, Inc., from December 1990 to October 1995, Mr. Keith
was Vice President of Sales & Marketing of the Company Compare Generiks, Inc.
("CGI") is a distributor, marketer and vendor of dietary supplements and
over-the-counter non-prescription pharmaceuticals.
Lawrence D. Simon has been a Director of the Company since March 11, 1998.
In addition, he has been the President, Chairman, Chief Financial Officer and a
Director of SSI since May 1, 1996. He was the National Sales Director for
Futurebiotics, Inc. from October 1, 1995, until his resignation on April 30,
1996. Prior to joining Futurebiotics, Inc., Mr. Simon was Regional Sales Manager
for the Company (from April 10, 1992 to September 30, 1995). Prior to PDK Labs
Inc., Mr. Simon was President of LDS Products Inc. (from March 1990 to March of
1991). LDS Products Inc., is a brokerage corporation specializing in sales to
wholesale companies in Eastern Europe. Prior to LDS Products Inc., Mr. Simon was
an Auditor with Coopers & Lybrand LLP (from December 1988 to March 1990). He is
a graduate of Cleveland State University with a Bachelors Degree in Business
Administration.
Ira Helman has served as a Director of the Company since August 1989. For
the past 30 years, Mr. Helman has been an independent investor and financial
consultant as well as a breeder and owner of harness horses. Mr. Helman receive
his B.A. degree from Princeton University and his law degree from Brooklyn Law
School.
4
<PAGE>
A. EXECUTIVE COMPENSATION.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
LONG TERM COMPENSATION
----------------------------------
ANNUAL COMPENSATION AWARDS PAYOUTS
------------------------------------ ---------- -------------------
(e) (f) (i)
OTHER RESTRICTED (g) (h) ALL
(a) (c) (d) ANNUAL STOCK OPTIONS/ LTIP OTHER
NAME AND PRINCIPAL (b) SALARY BONUS COMPENSATION AWARDS SARS PAYOUTS COMPENSATION
POSITION YEAR ($) ($) ($) ($) (#) ($) ($)
- -------------------------- ---- -------- -------- ------------ ---------- -------- ------- ------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Michael Krasnoff, former
CEO....................... 1998 $400,000 $400,000 $270,000(1) $318,750(2) -0- $ -0- $204,500(3)
1997 $400,000 $300,000 $ -0- $ -0- -0- $ -0- $ -0-
1996 $400,000 $250,000 $200,000(1) $ -0- -0- $ -0- $ -0-
Reginald Spinello, CEO.... 1998 $375,000(4) $300,000 $421,000(1) $595,000(5) -0- $ -0- $ -0-
1997 $250,000 $200,000 $ -0- $ -0- -0- $ -0- $ -0-
1996 $200,000(6) $150,000 $ -0- $ -0- -0- $ -0- $ -0-
Karine Hollander, CFO..... 1998 $160,000 $ 75,000 $160,000(1) $ -0- -0- $ -0- $ -0-
1997 $110,000 $ 60,000 $ -0- $ -0- -0- $ -0- $ -0-
1996 $ 85,000 $ -0- $ -0- $ -0- -0- $ -0- $ -0-
</TABLE>
- ------------------
(1) Represents reimbursements to pay taxes resulting from stock grants.
(2) Represents issuance of 150,000 shares in accordance with August 1998
consulting agreement. Shares were valued at $2.125 per share.
(3) Represents consulting fees paid in accordance with August 1998 agreement and
accrued vacation and sick pay in accordance with October 1995 Employment
Agreement.
(4) Represents salary of $325,000 paid by the Company and $50,000 paid by its
subsidiary.
(5) Represents issuance of 280,000 shares in accordance with August 1998
employment agreement. Shares were valued at $2.125 per share.
(6) Represents salary of $150,000 paid by the Company and $50,000 paid by its
subsidiary.
EMPLOYMENT AGREEMENTS
The Company has an employment agreement with Reginald Spinello, the
Company's Chief Executive Officer and President, which provides for a minimum
salary of $350,000 per year (the "Spinello Agreement"). Mr. Spinello was issued
280,000 shares of Common Stock pursuant to the Spinello Agreement.
On March 3, 1997, the Company's employment agreement with Karine Hollander,
was amended to appoint her as the Company's Chief Financial Officer at a minimum
salary of $110,000 per year (the "Hollander Agreement"). In October 1995,
Ms. Hollander was issued 50,000 shares of Common Stock pursuant to the Hollander
Agreement. On November 1, 1997, the Hollander Agreement was amended to increase
Ms. Hollander's salary to $160,000 per year with effect from December 8, 1997,
to remove all restrictions on the vesting of Ms. Hollander's shares and to
provide for reimbursement of all taxes incurred by Ms. Hollander with respect to
her shares. The Hollander Agreement terminates in October 2000 but may be
terminated by the Company, at its sole discretion, on ninety days notice.
5
<PAGE>
PROPOSAL NO. 2:
RATIFICATION OF SELECTION
OF HOLTZ RUBENSTEIN & CO., LLP
AS INDEPENDENT AUDITORS
The Board of Directors has selected the firm of Holtz Rubenstein & Co.,
LLP, independent certified public accountants, to audit the accounts for the
Company for Fiscal 1999. The firm of Holtz Rubenstein & Co., LLP has previously
audited the Company's financial statements. The Company is advised that neither
that firm nor any of its partners has any material direct or indirect
relationship with the Company. The Board of Directors considers Holtz
Rubenstein & Co., LLP to be well qualified for the function of serving as the
Company's auditors. The Delaware General Corporation Law does not require the
approval of the selection of auditors by the Company's stockholders, but in view
of the importance of the financial statements to stockholders, the Board of
Directors deems it desirable that they pass upon its selection of auditors. In
the event the stockholders disapprove of the selection, the Board of Directors
will consider the selection of other auditors. The Board of Directors recommends
that you vote in favor of the above proposal in view of the familiarity of Holtz
Rubenstein & Co., LLP with the Company's financial and other affairs due to its
previous service as auditors for the Company.
One or more representatives of Holtz Rubenstein & Co., LLP are expected to
be present at the Annual Meeting with the opportunity to make a statement if
they desire to do so, and are expected to be available to respond to appropriate
questions.
Unless otherwise directed by the stockholder giving the proxy, the proxy
will be voted "FOR" the ratification of the selection by the Board of Directors
of Holtz Rubenstein & Co., LLP as the Company's independent certified public
accountants for Fiscal 1999.
MISCELLANEOUS
REVOCATION OF PROXIES
If the Annual Meeting is adjourned, for whatever reason, the matters shall
be considered and voted upon by shareholders at the subsequent "adjourned or
postponed meeting", if any.
You may revoke your proxy at any time prior to its exercise by attending
the Annual Meeting and voting in person, although attendance at the Annual
Meeting will not in and of itself constitute revocation of a proxy, by giving
notice of revocation of your proxy at the Annual Meeting, or by delivering a
written notice of revocation or a duly executed proxy relating to the matters to
be considered at the Annual Meeting and bearing a later date to the Secretary of
the Company at 145 Ricefield Lane, Hauppauge, New York 11788. Unless revoked in
the manner set forth above, proxies on the form enclosed will be voted at the
Annual Meeting in accordance with your instructions.
INCORPORATED BY REFERENCE
The Company's Annual Report on Form 10-K for the year ended November 30,
1998 is attached hereto and is incorporated herein by reference.
ADDITIONAL AVAILABLE INFORMATION
The Company is subject to the informational filing requirements of the
Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and in
accordance therewith, the Company files periodic reports, proxy statements and
other information with the Commission under the Exchange Act relating to its
business, financial condition and other matters. The Company is required to
disclose in such proxy statements certain information as of particular dates,
concerning the Company's directors and officers, their remuneration, options
granted to them, the principal holders of the Company's securities and any
material interests of such persons in transactions with the Company. Such
reports, proxy statements and other information may be inspected at the
Commission's office
6
<PAGE>
at 450 Fifth Street, N.W., Washington, D.C. 20549. Copies may be obtained on
payment of the Commission's customary fees by writing to its principal office at
450 Fifth Street, N.W., Washington, D.C. 20549.
OTHER MATTERS
The Board of Directors of the Company does not intend to bring any other
matters before the Annual Meeting and does not know of any other matter that may
be brought before the Annual Meeting.
STOCKHOLDER'S PROPOSALS
Proposals of stockholders intended to be presented at the next annual
meeting must be received in writing, by the President of the Company at its
offices by January 31, 2000, in order to be considered for inclusion in the
Company's proxy statement relating to that meeting.
By Order of the Board of Directors
Reginald Spinello,
Chief Executive Officer and
President
7
<PAGE>
PDK LABS INC.
-------------
THIS PROXY IS SOLICITED ON BEHALF
OF THE BOARD OF DIRECTORS
The undersigned hereby appoints Reginald Spinello and Karine Hollander as
proxies (the "Proxies"), each with power of substitution and resubstitution, to
vote all shares of Common Stock, $.01 par value per share, of PDK Labs Inc. (the
"Company") held of record by the undersigned on September 2, 1999 at the Annual
Meeting of Stockholders to be held at the Sheraton Smithtown, 110 Vanderbilt
Motor Parkway, Smithtown, N.Y. 11788 on October 29, 1999 at 3:00 P.M. Eastern
Standard Time, or at any adjournments thereof, as directed on the reverse, and
in their discretion on all other matters coming before the meeting or any
adjournments thereof.
(Continued, and to be signed on the reverse side)
<PAGE>
Please date, sign and mail your proxy card back as soon as possible!
Annual Meeting of Stockholders
PDK LABS INC.
October 29, 1999
<PAGE>
o Please Detach and Mail in the Envelope Provided o
A /X/ Please mark your
votes as indicated
in this example.
VOTE FOR all
nominees named at VOTE WITHHELD
right (except as marked as to all nominees
to the contrary below) named at right
1. Election of five
(5) directors: / / / / Nominees: Reginald Spinello
Ira Helman
VOTE FOR all nominees named at Karine Hollander
right except those who may be Thomas Keith
named on this line: Lawrence Simon
- -----------------------------------------
FOR AGAINST ABSTAIN
2. Proposal to ratify appointment of / / / / / /
Holtz Rubenstein & Co., LLP as the
Company's independent certified
public accountants:
3. To consider and transact such other business as may properly come before
the Annual Meeting or any adjournments thereof.
In their discretion, the Proxies are authorized to vote upon such other
business as may properly come before the meeting.
When properly executed, this Proxy will be voted as directed. If no
direction is made, this Proxy will be voted "FOR" Proposals 1 and 2.
Please mark, date, sign and return this Proxy promptly in the enclosed envelope.
_________ _____________ ___________________________ Dated: ______, 1999
SIGNATURE PRINT NAME(S) SIGNATURE, IF HELD JOINTLY
NOTE: Please sign exactly as name appears hereon. When shares are held by
joint tenants, both should sign. When signing as attorney or executor,
administrator, trustee or guardian, please give full title as such. If a
corporation, please sign in full corporate name by president or other
authorized officer. If a partnership, please sign in partnership name by
authorized person.
